NAD+, NMN, and NR: The Longevity Molecule That Declines 50% by Middle Age

NAD+ Biology: Why It Matters

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in over 400 enzymatic reactions in human cells. It's critical for: ATP production (energy), DNA repair, circadian rhythm regulation, sirtuin activation (longevity proteins), immune function, and cellular stress responses.

In young adults, NAD+ levels are high. By age 50, they drop ~50%. By age 70, they're often <40% of youthful levels. This decline is associated with mitochondrial dysfunction, increased DNA damage, metabolic decline, and accelerated aging.

Why Levels Decline: NAD+ is consumed faster than it's synthesized. The main consumer is CD38 (a cell surface protein that increases with age and chronic inflammation), which degrades NAD+ to ADP-ribose. As we age, CD38 expression increases, consumption exceeds synthesis, and NAD+ drops.

NAD+ Precursors: NMN, NR, and Others

NAD+ cannot be directly supplemented (it's too large and charged to cross cell membranes efficiently). Instead, cells use precursors that are converted to NAD+ inside the cell.

Nicotinamide Riboside (NR): A nucleoside that enters cells and is converted to NMN, then to NAD+ via salvage pathways. Discovered in 2004 by Brenner. Available commercially (Niagen). Studied extensively.

Nicotinamide Mononucleotide (NMN): A nucleotide closer to NAD+ in the synthesis pathway. May require specific transporters (Slc12a8). Higher bioavailability than NR in some tissues. Studied intensively by David Sinclair's group.

Nicotinamide (Niacin): The simplest precursor. Also converted to NAD+. Cheap, well-studied, but less trendy because it's not proprietary.

The David Sinclair Research: Mice vs Humans

Mouse Studies: Sinclair's group (Harvard) has published over 50 papers showing that NMN and NR restore NAD+ levels in aging mice and improve multiple aging markers: mitochondrial function, insulin sensitivity, exercise capacity, endurance, healthspan, and lifespan extension.

Key 2013 study: aging mice given NMN showed restored muscle mitochondrial function and improved exercise capacity comparable to young mice. This is dramatic and consistently replicated.

Why Mice Aren't Humans: Mice live ~2 years. A study showing increased mouse lifespan is impressive but doesn't directly prove human longevity benefit. Mice metabolize compounds differently. Mice don't have human-equivalent complexity of aging.

Human Trials: The Gap in Evidence

The CLOCK Trial (2021): The largest human trial to date. 12 weeks, 120 people, NMN 250 mg daily or placebo. Primary outcome: fasting glucose and insulin sensitivity. Results: NMN improved fasting glucose and insulin sensitivity compared to placebo. Effect size modest but real (Lowe et al. 2022 in Science Translational Medicine).

Other Human Studies: Several smaller trials (20-30 people each) show that NMN and NR improve metabolic markers (glucose, insulin, lipids), blood pressure, and physical function. Most are recent (2020+), sample sizes small, and follow-up periods short (8-12 weeks).

What's Missing: No human lifespan extension data (would require decades). No large long-term safety studies. Effects on brain aging, cognition, or disease prevention not rigorously tested in humans. Most studies measure biomarkers (blood work, fitness tests), not actual health outcomes.

NMN vs NR: Which Works Better?

The Debate: Sinclair promotes NMN as superior. Others promote NR (cheaper, already commercial). The truth: limited human data comparing them directly.

Preclinical Evidence: In cells and mice, NMN appears marginally more potent because it's one step closer to NAD+. But absorption differs between tissues. In some animal tissues, NR converts efficiently; in others, NMN works better. Human tissue bioavailability unknown.

Practical Answer: Both work in humans, based on the limited data. NMN likely slightly more potent but more expensive (often £50-100/month vs £20-40/month for NR). If cost matters, NR is reasonable. If you want the "best," NMN has slightly more data, though the difference is modest.

CD38 Inhibitors: The Emerging Strategy

Instead of boosting NAD+ synthesis, an alternative is reducing NAD+ consumption by blocking CD38. Several natural compounds inhibit CD38:

Quercetin: A flavonoid in apple skins, red wine, tea. In vitro studies show CD38 inhibition. Human data limited. Typical dose: 250-500 mg daily.

Apigenin: A flavone in chamomile, celery, parsley. Inhibits CD38 in laboratory studies. Almost no human evidence. Dose unknown.

The idea: take a CD38 inhibitor plus an NAD+ precursor. CD38 is slowed, NAD+ synthesis is boosted, and levels potentially increase more than either alone. This is theoretically sensible but untested in humans.

IV NAD+ Clinics

Some aesthetic and anti-aging clinics offer IV NAD+ infusions (500-1000 mg weekly), claiming dramatic effects on energy, cognition, and aging. Cost: £200-500 per infusion.

The Problem: No robust human trial data supports IV NAD+ for anti-aging. The rationale is that IV bypasses absorption issues and delivers higher doses systemically. Mechanistically plausible. But evidence is anecdotal. Much of the hype is driven by clinic marketing, not science.

Safety: IV NAD+ is generally tolerated but not studied in long-term protocols. Flushing, discomfort at injection site, and temporary increase in blood pressure reported.

Practical Dosing and Expectations

NMN: 250-500 mg daily. Effects on biomarkers observable at 8-12 weeks. Human health outcome benefit unknown.

NR: 250-1000 mg daily. Similar timeline.

Nicotinamide: 500-1000 mg daily. Works in theory, less studied, cheap.

Realistic Expectation: NAD+ boosting is a tool for metabolic optimization. It improves insulin sensitivity, mitochondrial function, and may slow some aging markers. It's not a longevity pill. It's one strategy among many (exercise, sleep, nutrition, stress management all matter more).